46 results about "Heparin-binding protein" patented technology

The invention relates to the technical field of clinical infectious disease marker detection, in particular to heparin binding protein detection test paper for immunomicrosphere chromatography detection. A method includes the following steps that a calibration curve is prepared; a detection buffer solution containing rabbit anti-human heparin binding protein antibody is prepared, fluorescent or colorful latex microsphere-marked chicken anti-rabbit antibody is prepared, a sample pad coats a solid phase, a detection line coated with a mouse anti-human heparin binding protein antibody and a reaction pad coated with a goat anti-rabbit antibody quality control line are prepared, a separation membrane is assembled, a test paper strip is assembled, a clinical sample is detected, and the dried test paper strip is placed in an aluminum foil bag. The heparin binding protein detection test paper for fluorescence chromatography detection has high cost effectiveness, and the level of heparin binding protein in body fluids of patients is quantitatively detected and evaluated. The method is used for a POCT detection system and screening or detection of changes of heparin binding protein in the body fluids of the patients to determine a detection method of infectious disease markers so that the heparin binding protein detection technology can become a clinical conventional detection project.

The invention relates to the technical field of medical supplies, and particularly discloses a kit for detecting heparin binding protein through immunofluorescence chromatography and a preparation method of the kit. The kit comprises a first buffer solution, a second buffer solution and a reagent card. The first buffer solution is a phosphate buffer solution containing rabbit anti-human heparin binding protein antibodies, wherein the concentration of the rabbit anti-human heparin binding protein antibodies is 0.83-2 nanograms per microliter. The second buffer solution is a phosphate buffer solution containing fluorescently-labeled affinipure chicken anti-rabbit, wherein the concentration of fluorescently-labeled affinipure chicken anti-rabbit is 0.05-0.2 microgram per microliter. The reagent card comprises a plastic cushion plate. A nitrocellulose membrane is arranged on the plastic cushion plate. A detection line and a quality control line are arranged on the nitrocellulose membrane in a spaced and left-right mode, a glass cellulose membrane is arranged on the portion, on the left side of the detection line, of the nitrocellulose membrane. A piece of water absorption paper is arranged on the portion, on the right side of the quality control line, of the nitrocellulose membrane. A blood filter membrane is arranged on the glass cellulose membrane. The detection line is wrapped by rabbit anti-human heparin binding protein antibodies. The quality control line is wrapped by goat anti-rabbit antibodies. The kit has a good linear range and is high in flexibility and accuracy.

The invention provides a heparin binding protein detection kit. A double-antibody sandwich method is adopted and is characterized by comprising the following steps: coating micropores of an ELISA plate with HBP monoclonal antibodies, diluting HBP in plasma as antigen substance by using a sample diluting solution, and combining the antigen substance with the HBP monoclonal antibodies coating a solid phase to form a solid phase-antibody-antigen complex in a first incubation period; fully washing uncombined components by using a washing buffer solution, adding an enzyme conjugate for incubation, and combining the enzyme conjugate with the solid phase-antibody-antigen complex; further washing, removing uncombined components, adding a substrate for incubation, catalyzing the substrate via enzyme to prepare a coloured product, adding a stop solution for stopping reacting, and detecting optical density values of various pores via an enzyme labeling instrument, wherein the size of the optical density values is in positive correlation with the concentration of HBP in the plasma. The heparin binding protein detection kit is a novel immune detection kit for quantitatively detecting heparin binding protein in human plasma in vitro and can contribute strength to medical examination and human health.

Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors to the native heparin molecules that are retained within the graft material. Such graft materials may be used in methods for the treatment of wounds in patients.

The embodiments of the invention relate to the field of immunoassay, and in particular to a human heparin binding protein assay kit with high sensitivity and wide detection range. The human heparin binding protein assay kit comprises: a reagent 1, a reagent 2 and human HBP calibrators with different concentration gradients. The reagent 2 comprises a carboxyl latex microsphere labeled only with human HBP monoclonal antibody and a carboxyl latex microsphere labeled only with human HBP polyclonal antibody. The average particle diameter of the carboxyl latex microsphere labeled only with the humanHBP monoclonal antibody > the average particle diameter of the carboxyl latex microsphere labeled only with the human HBP polyclonal antibody. The human heparin binding protein assay kit provided bythe invention can complete a single sample test within 10 minutes, and indexes of precision, accuracy and anti-interference are excellent. The invention can be used clinically to predict an organ dysfunction caused by sepsis, and can be used as an early diagnostic marker for sepsis, especially serious bacterial infection.

A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the resultant ligated cDNA. This heparan sulfate sugar chain-modified heparin-binding protein is functionalized by covalently bonding thereto glycosaminoglycan sugar chains containing little chondroitin sulfate. For example, this heparin-binding protein is excellent in stabilities, such as thermostability, acid resistance, alkali resistance and in vivo stability. Further, the heparan sulfate sugar chain-modified heparin-binding protein is effective in cell proliferation and tissue regeneration, and has effect of regulating the physiological functions of FGFs. Thus, this heparin-binding protein is extremely useful as a medicine for preventing or treating various FGF-related diseases.

The present invention aims at providing a medicament and a method for promoting replication of hepatocytes and a medicament and a method for ameliorating insulin resistance. An effective amount of a neutralizing agent for CXCL10 belonging to a subfamily of chemokines which are heparin-binding proteins is administered to the hepatocytes to promote the replication of the hepatocytes. As the neutralizing agent for CXCL10, a factor which is specifically bound to CXCL10 and inhibits an activity of CXCL10 or a factor which inhibits CXCL10 expression is suitably used. By administering the neutralizing agent to impaired hepatic tissue, it is possible to restore and regenerate the hepatic tissue. Meanwhile, by administering an effective amount of the neutralizing agent for CXCL10 to the hepatocytes, the insulin resistance in type II diabetes and metabolic syndrome is ameliorated.

The invention provides a dry immunofluorescence quantitative method heparin binding protein (HBP) detection kit. The kit comprises a reagent strip, the reagent strip comprises absorbent paper, a nitrocellulose membrane and a sample pad, the absorbent paper is located at one end of the nitrocellulose membrane, the sample pad is located at the other end of the nitrocellulose membrane, and the nitrocellulose membrane is sequentially coated with a quality control C line, a detection T line and a fluorescent antibody solidus; a novel fluorescence labeling process, a sample pad treating fluid and afluorescence marker immobilization process are adopted to rapidly, accurately and quantitatively detect heparin binding protein HBP in human plasma with high sensitivity, so that the problems that labeled fluorescent substances are unstable and later process control is not facilitated are solved; meanwhile, the fluorescent antibody is immobilized on the nitrocellulose membrane instead of a specialfluorescent binding pad, so that the precision is remarkably improved on the basis of widening the storage conditions of the kit.

Provided is a reagent for assaying a thrombin-antithrombin complex (TAT) in a blood sample from a subject by latex agglutination assay. The reagent includes a polycation. As a result, TAT complexes can be precisely assayed while circumventing the effect of heparin. The polycation is, for example, hexadimethrine bromide, chitosans, modified dextran, aminodextran, hydroxymethyl cellulose trimethylamine, lysozyme, spermine, spermidine, polylysine, polyarginine, polyornithine, protamine sulfate, hydroxyethyl cellulose trimethylamine, heparin-binding protein, polyallylamine, polyallylamine hydrochloride, poly(diallyl dialkyl amine), polyamideamine, polyamine, polyvinylbenzyltrimethylammonium chloride, polydiallyldimethylammonium chloride, polyethyleneimine, polypropyleneimine, polypropylethyleneimine, polyimidazoline, polyvinylamine, polyvinyl pyridine, poly(acrylamide/methacryloxypropyltrimethylammonium bromide), poly(diaryldimethylammonium chloride/N-isopropylacrylamide), poly(dimethylaminoethyl acrylate/acrylamide), poly(dimethylaminoethyl methacrylate), polydimethylaminoepichlorohydrin, polyethyleneiminoepichlorohydrin, polymethacryloxyethyl-trimethylammonium bromide, hydroxypropylmethacryloyloxyethyl dimethyl ammonium chloride, poly(methyldiethylaminoethylmethacrylate/acrylamide), poly(methyl/guanidine), polymethylvinylpyridinium bromide, poly(vinylpyrrolidone-dimethylaminoethyl methacrylate), or polyvinylmethylpyridinium bromide.

The invention discloses a single-reagent heparin binding protein (HBP) detection reagent kit and a method for preparing the same. The single-reagent heparin binding protein detection reagent kit is asingle-reagent detection reagent kit. Main components of the single-reagent detection reagent kit include reaction liquid, standard products with HBP and quality control products. The reaction liquidcomprises HBP antibody labeling latex particles and further comprises buffer solution, surfactants, salt, stabilizers, suspending agents and preservatives. The invention further discloses a method fordetecting the concentration of the HBP in blood samples by the aid of the single-reagent heparin binding protein detection reagent kit. The single-reagent heparin binding protein detection reagent kit and the methods have the advantage that the single-reagent heparin binding protein detection reagent kit comprises a single reagent, is easy to operate, high in sensitivity and wide in linear rangeand can be widely applied to various transmission or scattering analyzers including universal biochemical analyzers, specific protein analyzers and the like.

The present invention relates to a method for producing a mammalian heparin-binding protein in a mammalian cell that can be cultured under anaerobic conditions after introducing a nucleic acid encoding as heparin-binding protein into said cell with comprising (a) introducing into said mammalian cell a nucleic acid encoding said heparin-binding protein; (b) culturing the cell of step (a) under conditions conducive to expression of said HBP; and (c) recovering said HBP from the culture medium. Furthermore, the invention relates to the recombinant mammalian cell used in the method.

The invention relates to a kit for quantitatively detecting HBP by using magnetic micro-particle chemiluminiscence, a preparation method and a detection method thereof. The kit comprises an HBP calibrator, an HBP reagent 1, an HBP reagent 2, an HBP magnetic separation reagent and an HBP quality control material, wherein the HBP calibrator comprises six levels, and is composed of HBP antigens withdifferent concentrations and a Tris buffer solution containing bovine serum albumin, the HBP reagent 1 is prepared from biotin ester labeled HBP-Ab and a Tris buffer solution containing bovine serum albumin, the HBP reagent 2 comprises an alkaline phosphatase labeled HBP-Ab and a Tris buffer solution containing bovine serum albumin, the HBP magnetic separation reagent comprises streptavidin labeled magnetic micro particles and a Tris buffer solution containing bovine serum albumin, and the HBP quality control material comprises two quality control levels, and is composed of HBP antigens with different concentrations and a Tris buffer solution containing bovine serum albumin. The kit can be prepared at a low cost, and can realize accurate and high-precision quantitative determination of human heparin binding protein (HBP).

A heparin-binding protein functionalized by covalently bonding thereto a sugar chain, a method for producing the protein and a pharmaceutical composition containing the protein as an active ingredient, as well as a method for functionalizing a natural protein having no sugar chain by covalently bonding thereto a sugar chain.

The invention discloses a heparin-binding protein assay kit applying a magnetic particle chemiluminescence enzyme immunoassay method. The heparin-binding protein assay kit comprises avidin-labeled magnetic particles, a biotin-labeled HBP antibody 1, a horseradish peroxidase-labeled HBP antibody 2, an HBP calibrator, a concentrated washing liquid and a substrate. The invention also discloses a preparation method and a determination method of the kit. The novel immunoassay kit disclosed by the invention is used for quantitatively assaying HBP in human body fluid in vitro, overcomes personal errors of a traditional enzyme immunoassay (EIA) method in the aspect of operation, can quantitatively and objectively reflect the existence of HBP, and provides a more powerful experimental diagnosis basis for clinical diagnosis, curative effect observation and prognosis judgment. The heparin binding protein determination method provided by the invention is high in specificity, good in repeatability,high in detection sensitivity, wide in linear range, high in automation degree and simple, convenient and rapid to operate; compared with an EIA method, the method has the advantages of rapidness, simplicity, convenience, accuracy and small interference.